Duvelisib for CLL/SLL and follicular non-Hodgkin lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibito...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood 2019-11, Vol.134 (19), p.1573-1577
Hauptverfasser:	Patel, Krish, Danilov, Alexey V., Pagel, John M.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Agents - therapeutic use Blood Spotlight Clinical Trials and Observations Humans Isoquinolines - therapeutic use Leukemia, Lymphocytic, Chronic, B-Cell - drug therapy Lymphoid Neoplasia Lymphoma, Follicular - drug therapy Purines - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and follicular lymphoma (FL) represent indolent malignancies characterized by multiple episodes of relapse. Therapy has centered on agents that largely target the B-cell receptor pathway. Duvelisib is a second-generation oral inhibitor of phosphoinositide-3 kinase, downstream of the B-cell receptor pathway, approved in the United States for relapsed CLL/SLL and FL. Duvelisib represents a highly active agent, and ongoing investigations, including fixed-duration drug combinations and alternative dosing schedules, are aimed at reducing immune-mediated toxicities. [Display omitted]
ISSN:	0006-4971 1528-0020
DOI:	10.1182/blood.2019001795